OncLive TV

Daniel A. Vorobiof, MD, discusses financial toxicity in oncology.

Sagar Lonial, MD, FACP, discusses the role of BCMA ​as a target in multiple myeloma.

Sandip P. Patel, MD, discusses the role of immunotherapy combinations in lung cancer.

Brandon Mahal, MD, assistant professor of radiation oncology, assistant director of community outreach and engagement, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the prevalence of prostate cancer among African American men. 

Ritu Salani, MD, MBA, discusses therapeutic advances in endometrial cancer.

Geoffrey T. Gibney, MD, discusses selecting between BRAF inhibitor regimens in melanoma.

Charles Schiffer, MD, discusses factors to consider for TKI discontinuation in chronic myeloid leukemia.

Nilofer S​aba Azad, MD, discusses selecting between regorafenib and TAS-102 in colorectal cancer.

William D. Tap, MD, discusses the rise of precision medicine in sarcoma.

Gina Z. D'Amato, MD, discusses the importance of multidisciplinary care in sarcoma.

Daniel H. Ahn, DO, discusses the identification of NTRK alterations in colorectal cancer.

Michael B. Atkins, MD, discusses the expanding role of immunotherapy in oncology.

William D. Tap, MD, discusses the importance of ​community and academic collaboration in sarcoma.

Alexander Spira, MD, PhD, FACP, discusses the rationale of the phase 1 CHRYSALIS trial with amivantamab plus lazertinib in EGFR-mutant non–small cell lung cancer.

Ezra Cohen, MD, FRCPSC, FASCO, discusses the design of the phase 2 SPEARHEAD-2 trial with ADP-A2M4 plus pembrolizumab in patients with recurrent or metastatic head and neck cancer.

Neal D. Shore, MD, FACS, discusses the need for further education on molecular testing for metastatic castration-resistant prostate cancer.

Edward Wolin, MD, discusses the current treatment landscape of neuroendocrine tumors.

Laura Goff, MD, discusses the need to identify novel targets in hepatocellular carcinoma.

Shubham Pant, MD, discusses the role of genetic testing in pancreatic cancer.

Nilofer S​aba Azad, MD, discusses third-line treatment options for patients with colorectal cancer.

Elizabeth Petri Henske, MD, discusses the potential role of glutathione in chromophobe renal cell carcinoma.

Hans Hammers, MD, PhD, discusses investigational strategies that are being used to inflame tumors in renal cell carcinoma.

Jason J. Luke, MD, FACP, discusses the importance of BRAF in melanoma.

Jeffrey S. Weber, MD, PhD, discusses the results of the phase 3 COMBI-AD trial with dabrafenib plus trametinib in patients with resected, stage III BRAF V600E/K–mutant melanoma.

Benjamin P. Levy, MD, discusses the mechanism ​of action of telaglenastat in non–small cell lung cancer.

Debu Tripathy, MD, discusses treatment de-escalation in HER2-positive breast cancer.

William J. Gradishar, MD, discusses the expanding role of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Nathan Bahary, MD, PhD, discusses the prognosis of BRAF-mutant colorectal cancer.

Pashtoon M. Kasi, MD, MS, discusses the role of minimal residual disease testing in colorectal cancer.

Jean-Philippe Theurillat, MD, discusses castration and androgen receptor inhibition in prostate cancer.